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Abstracts / Biol Blood Marrow Transplant 21 (2015) S127eS146 S139The aim of our study was to review toxicities related to the
continuation of cART during chemotherapy in HIV-infected
patients undergoing autologous stem cell transplants (ASCT)
for haematological malignancies.
This was a retrospective study, which included HIV-
infected patients who were on cART and underwent ASCT
for a haematological malignancy from January 1st 2003 to
December 31st 2013 at a single institution. We reviewed
adverse effects related to the use cART during conditioning
chemotherapy.
A total of 11 patients were included, n¼1 acute myeloid
leukemia (AML), n¼4 multiple myeloma (MM), n¼4 Burkitt
lymphoma, n¼1 plasmablastic lymphoma, n¼1 primary
effusion lymphoma and n¼1 Hodgkin lymphoma. Of the 11
patients, 6 (54%) were on non-Protease inhibitor (PI) and 5
(56%) were on PI based cART during their transplant. NoTRM
were observed; all patients continued cART during
conditioning chemotherapy. 6 Patients relapsed, 2 were
salvaged by allogeneic HSCT, and 2 MM patients were given
salvage treatment. There were 5 non-treatment related
deaths, n¼1 developed secondary malignancy, n¼1 relapsed
AML, n¼2 relapsed MM and one patient died due to
zidovudine induced lactic acidosis 10 months post ASCT.
Overall survival from ranged from 1-8 yrs.
This case series demonstrated that concomitant use of
cART during conditioning chemotherapy for patients
undergoing ASCT does not adversely affect treatment
outcomes. Therefore, we recommend continuing cART
during ASCT. However, we recommend avoiding zidovudine
during conditioning chemotherapy due to high risk of
myelosuppression.Figure 1. Progression free in survival among Caucasian patients compared to
African American patients during the 24-month follow-up period (Log Rank¼
0.03).157
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Background: The incidence of CMV after ASCT is much lower
(1-9%) than after allogeneic transplantation. However, with
recent use of R, there has been increasing concern about
opportunistic infections. The objective of our study was to
determine the disease burden and characteristics of CMV
infection/reactivation after ASCT in recent years.
Methods: Records were searched in Karmanos Cancer Center
database for the occurrence of CMV infection/disease during
the post-transplantation period in patients undergoing ASCT
between December 2007 and December 2013. Charts were
reviewed retrospectively to identify characteristics of CMV
infection/reactivation/disease, demographic features and
outcomes of the affected patients.
Results: Seven of 978 ASCT recipients {multiple myeloma
(MM): 601 patients (pts), non-Hodgkins lymphoma (NHL):
252 pts, Hodgkins lymphoma (HD): 99 pts} were found to be
viremic by CMV PCR within the ﬁrst 3 months after trans-
plant, during work up for antibiotic-resistant fever. The
median time for development of CMV PCR positive status
was 33 days post-transplantation (range, 18e78 days). CMV
viremia developed in 3 of the 236 patients who received R
with induction or preparative regimens as compared to 4 of
742 who did not receive R (p¼0.2). In all 7 patients, viremia
developed after neutrophil engraftment.
Of the 7 patients, 3 developed bacterial and/or fungal
infection within 60 days from onset of viremia. Median levelof CMV viremia was 16,912 copies/ml (range, 724e33,100) in
these 3 patients. All 3 patients received anti-viral and other
appropriate anti-microbial therapy. The viremia resolved in a
median of 17.5 days (range, 9e26 days). One of these patients
died at 28 days from onset of CMV viremia due to invasive
candidiasis and septic shock.
The remaining 4 patients, who did not develop bacterial
or fungal infection within 60 days from viremia, had median
CMV copies/ml of 700 (range, 250e1707). Only one of these
4 patients received anti-CMV therapy but he died shortly,
thereafter (at 19 days from onset of viremia), due to pro-
gression of primary malignancy.
None of the 7 patients had documented evidence of tissue
invasive CMV disease.
Conclusion: Despite the use of R prior to ASCT, frequency of
CMV infection/disease remains low in this population. Low
level of CMV viremia does not appear to warrant therapy.
Higher levels of viremia were associated with development
of subsequent bacterial/fungal infections.158
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Background: Upfront ASCT in eligible patients (pts) is
currently considered a standard of care and has been shown
to improve disease free survival and overall survival (OS) in
randomized trials. The incidence of MM in AA population is
twice compared to the Caucasian (C) population and the
mortality rates are higher in AA pts with MM. The plausible
reasons for this are higher incidence of poor risk disease, less
upfront exposure to novel agents, lower referral rate for ASCT
and poor access to health care. The aim of our study is to
identify differences in clinical characteristics and outcomes
in two groups.
Methods: We performed a retrospective analysis in MM pts
who underwent ASCT at Karmanos Cancer Center between
